

Фітотерапія Часопис

Науково-практичне фахове видання

Голова редакційної ради

- Гарник Т. П., д-р мед. наук, проф. (м. Київ)

Редакційна рада

- Абрамов С. В., канд. мед. наук, доцент (м. Дніпро)
- Андріюк Л. В., д-р мед. наук, проф. (м. Львів)
- Білай І. М., д-р медичних наук, проф. (м. Запоріжжя)
- Волошин О. І., д-р мед. наук, проф. (м. Чернівці)
- Глоба О. П., д-р пед. наук, проф. (м. Київ)
- Горова Е. В., канд. мед. наук, доцент (м. Київ)
- Дарзулі Н. П., канд. фарм. наук (м. Тернопіль)
- Добровольська Н. А., д-р псих. наук, доцент (м. Київ)
(заступник головного редактора)
- Колосова І. І., канд. біол. наук (м. Дніпро)
- Кравченко В. М., д-р біол. наук, проф. (м. Харків)
- Лоскутова І. В., д-р медичних наук, проф. (м. Кропивницький)
- Маїčiulskytė Sonata, д-р медицини, проф. (м. Клайпеда, Литва)
- Островська С. С., д-р біол. наук, проф. (м. Дніпро)
- Сепідех Парчамі Газае, канд. біол. наук (м. Київ)
- Радиш Я. Ф., д-р наук з держ. упр., канд. мед. наук, проф. (м. Київ)
- Соколовський С. І., канд. мед. наук, доцент (м. Дніпро)
- Хворост О. П., д-р фарм. наук (м. Харків)
- Шусть В. В., канд. пед. наук, доцент (м. Київ)
(відповідальний секретар)

Електронна сторінка журналу –
phytotherapy.vernadskyjournals.in.ua



Видавничий дім
«Гельветика»
2024

Головний редактор

- Горчакова Н. О., д-р мед. наук, проф. (м. Київ)

Редакційна колегія

- Антонова-Рафі Ю. В., канд. техн. наук, доцент (м. Київ)
- Байбаков В. М., д-р мед. наук, проф. (м. Дніпро)
(заступник головного редактора)
- Бленічев І. Ф., д-р біол. наук, проф. (м. Запоріжжя)
(науковий редактор)
- Боднар О. І., д-р біол. наук, доцент (м. Тернопіль)
- Бурда Н. Є., д-р фарм. наук, доцент (м. Харків)
(заступник наукового редактора)
- Весельський С. П., д-р біол. наук, с. н. с. (м. Київ)
- Віргінія Кукула-Кох, проф. (Польща)
- Галкін О. Ю., д-р біол. наук, проф. (м. Київ)
- Гарасєв Е., д-р фарм. наук, проф. (Азербайджан)
- Гладишев В. В., д-р фарм. наук, проф. (м. Запоріжжя)
- Григоренко Л. В., д-р мед. наук, доцент (м. Дніпро)
- Дроздова А. О., д-р фарм. наук, проф. (м. Київ)
- Дуда Жанна, д-р наук, проф. (Мексика)
- Кириченко А. Г., MD, PD, проф. (м. Дніпро)
- Кисличенко В. С., д-р фарм. наук, професор (м. Харків)
- Коваленко О. Є., д-р мед. наук, проф. (м. Київ)
- Ковальова О. В., канд. мед. наук, доцент (м. Запоріжжя)
- Копчак О. О., д-р мед. наук, старший дослідник (м. Київ)
- Костильола Вінченцо (Vincenzo Costigliola),
д-р медицини (Бельгія)
- Кузнєцова В. Ю., д-р фарм. наук, доцент (м. Харків)
- Кучменко О. Б., д-р біол. наук, проф. (м. Ніжин, Чернігівська обл.)
- Марчишин С. М., д-р фарм. наук, проф. (м. Тернопіль)
- Мінарченко В. М., д-р біол. наук, проф. (м. Київ)
- Марушко Ю. В., д-р мед. наук, проф. (м. Київ)
- Москевіцієнė Daiva, д-р медицини, проф. (м. Клайпеда, Литва)
- Ніженковська І. В., д-р мед. наук, проф. (м. Київ)
- Пузиренко Андрій, MD, PhD (Вісконсін, США)
- Разумний Р. В., д-р мед. наук, проф. (м. Дніпро)
- Рибак В. А., д-р біол. наук, проф. (м. Харків)
- Тітов Г. І., MD, PhD, проф. (м. Дніпро)
(заступник головного редактора)
- Угіс Клетніекс, Dг.МВА (Латвія)
- Худецький І. Ю., д-р мед. наук, професор (м. Київ)
- Шаторна В. Ф., д-р біол. наук, проф. (м. Дніпро)
- Шумна Т. Є., MD, PD, проф. (м. Дніпро)

© Таврійський національний університет імені В.І. Вернадського, 2024
© ТОВ «Європейський медичний університет», м. Дніпро, 2024
© Всеукраїнська громадська організація «Асоціація фахівців з народної і нетрадиційної медицини України», 2024

ЗМІСТ / CONTENTS

МЕДИЦИНА MEDICINE

Nadiya GORCHAKOVA, Igor BELENICHEV, Tatyana HARNYK, Ganna ZAYCHENKO, Olena KLYMENKO, Ella GOROVA, Olena SHUMEYKO, Iryna MASLOVA Stress protection properties of phytoodrugs.....	5
Надія ГОРЧАКОВА, Ігор БЄЛЕНІЧЕВ, Тетяна ГАРНИК, Ганна ЗАЙЧЕНКО, Олена КЛИМЕНКО, Елла ГОРОВА, Олена ШУМЕЙКО, Ірина МАСЛОВА Стреспротекторні властивості фітопрепаратів	15
Ganna ZAYCHENKO, Andrii DOROSHENKO, Kostiantyn DOROSHENKO Peculiarities of clinical trials in complementary and alternative medicine	25
Лілія БАБІНЕЦЬ, Ірина ГАЛАБІЦЬКА Ефективність системної ензимотерапії у комплексному лікуванні остеоартрозу	32
Віктор ГОРДІЄНКО, Оlesia ПЕРЕПЕЛИЦЯ, Надія ГОРЧАКОВА, Тетяна ГАРНИК, Ірина ГОРДІЄНКО Грелін – нейрогуморальний регулятор фізіологічних процесів в організмі (огляд літератури).....	40
Ganna ZAYCHENKO, Nadiya GORCHAKOVA, Anna HORBACH, Iryna STAN, Pavlo SIMONOV Theoretical and experimental justification of development of dermatological medicinal products based on natural compounds of Naftalan oil.....	52
Ganna NEVOIT, Olena FILYUNOVA, Oksana KITURA, Ozar MINTSER, Maksim POTYAZHENKO, Inga Arune BUMBLYTE, Alfonsas VAINORAS Biophotonics and reflexology: conceptualization of the role of biophotonic signaling.....	62
Anatoliy DIUDIUN, Andriy GUBAR, Mykyta POLION, Natalia POLION, Nadiia HLADKYKH, Ivan KRYZHANOVSKYI The role of sexually transmitted infections in the onset and development of chronic bacterial prostatitis	79
Anatoly LEVYTSKY, Iryna SELIVANSKA, Vladyslav VELYCHKO Integrated biochemical determination of the therapeutic and preventive effectiveness of herbal remedies for liver damage in rats that consumed fried sunflower oil	86
Лариса ВОЛОШИНА, Наталія БАЧУК-ПОНІЧ, Марина ПАТРАТІЙ, Валентина ВАСЮК, Ірина ОКІПНЯК Куркума (<i>Curcuma longa</i>) як спеція і лікарська рослина: високі позиції та перспективи використання у сучасній медицині крізь призму новітніх досліджень (огляд літератури).....	92

ФІЗИЧНА ТЕРАПІЯ. ЕРГОТЕРАПІЯ. ДИСКУСІЇ PHISICAL THERAPY. ERGOTHERAPY. DISCUSSIONS

Yurii VYKHLIAIEV, Liudmyla DUDOROVA, Nadiya PETSSENKO, Sergey CHERNOVSKY Health and treatment factors of using phytotherapy (literature review).....	101
Юрій ВИХЛЯЄВ, Людмила ДУДОРОВА, Надія ПЕЦЕНКО, Сергій ЧЕРНОВСЬКИЙ Оздоровчо-лікувальні чинники застосування засобів фітотерапії (огляд літератури).....	110

МЕДИЦИНА MEDICINE

Nadiya GORCHAKOVA, Igor BELENICHEV, Tatyana HARNYK, Ganna ZAYCHENKO, Olena KLYMENKO, Ella GOROVA, Olena SHUMEYKO, Iryna MASLOVA Stress protection properties of phytoodrugs.....	5
Nadiya GORCHAKOVA, Igor BELENICHEV, Tatyana HARNYK, Ganna ZAYCHENKO, Olena KLYMENKO, Ella GOROVA, Olena SHUMEYKO, Iryna MASLOVA Stress protection properties of phytoodrugs.....	15
Ganna ZAYCHENKO, Andrii DOROSHENKO, Kostiantyn DOROSHENKO Peculiarities of clinical trials in complementary and alternative medicine	25
Lilia BABINETS, Iryna HALABITSKA Efficiency of systemic enzymotherapy in the complex treatment of osteoarthritis	32
Viktor GORDIENKO, Olesia PEREPELYTSIA, Nadiya GORCHAKOVA, Tatyana HARNYK, Iryna GORDIENKO Ghrelin – a neurohumoral regulator of physiological processes in the body (literature review).....	40
Ganna ZAYCHENKO, Nadiya GORCHAKOVA, Anna HORBACH, Iryna STAN, Pavlo SIMONOV Theoretical and experimental justification of development of dermatological medicinal products based on natural compounds of Naftalan oil.....	52
Ganna NEVOIT, Olena FILYUNOVA, Oksana KITURA, Ozar MINTSER, Maksim POTYAZHENKO, Inga Arune BUMBLYTE, Alfonsas VAINORAS Biophotonics and reflexology: conceptualization of the role of biophotonic signaling.....	62
Anatoliy DIUDIUN, Andriy GUBAR, Mykyta POLION, Natalia POLION, Nadiia HLADKYKH, Ivan KRYZHANOVSKYI The role of sexually transmitted infections in the onset and development of chronic bacterial prostatitis	79
Anatoly LEVYTSKY, Iryna SELIVANSKA, Vladyslav VELYCHKO Integrated biochemical determination of the therapeutic and preventive effectiveness of herbal remedies for liver damage in rats that consumed fried sunflower oil	86
Larysa VOLOSHYNA, Nataliia BACHUK-PONYCH, Maryna PATRATIY, Valentina VASYUK, Iryna OKIPNYAK Turmeric (<i>Curcuma longa</i>), as a spice and a medicinal plant: high positions and prospects of use in modern medicine through the prism of the latest research (literature review).....	92

ФІЗИЧНА ТЕРАПІЯ. ЕРГОТЕРАПІЯ. ДИСКУСІЇ PHISICAL THERAPY. ERGOTHERAPY. DISCUSSIONS

Yurii VYKHLIAIEV, Liudmyla DUDOROVA, Nadiya PETSSENKO, Sergey CHERNOVSKY Health and treatment factors of using phytotherapy (literature review).....	101
Yurii VYKHLIAIEV, Liudmyla DUDOROVA, Nadiya PETSSENKO, Sergey CHERNOVSKY Health and treatment factors of using phytotherapy (literature review).....	110

UDC 616.65-002-093-098

Anatoliy DIUDIUN

Doctor of Medicine, Professor of the Department of Internal Medicine, European Medical University, Academician Dzyak George str., 3, Dnipro, Ukraine, 49005 (anatolijdudun@gmail.com)

ORCID: 0000-0002-8374-3023

Andriy GUBAR

Candidate of Medical Sciences, Associate Professor of the Department of Urology, Zaporizhzhya State Medical and Pharmaceutical University, Mayakovskoho ave., 26, Zaporizhzhya, Ukraine, 69035 (andreygubar76@gmail.com)

ORCID: 0000-0002-8198-128X

Mykyta POLION

Candidate of Medical Sciences, Associate Professor of the Department of Surgery #1 and Urology, Dnipro State Medical University, Volodymyr Vernadsky str., 9, Dnipro, Ukraine, 49044 (polion.mykyta@gmail.com)

ORCID: 0000-0001-9307-1411

Natalia POLION

Candidate of Medical Sciences, Dermatovenerologist, Municipal Non-Profit Enterprise «City Clinical Hospital No. 16» Bohdana Khmelnytskoho ave., 19, Dnipro, Ukraine, 49000 (nnpolion@gmail.com)

ORCID: 0000-0002-5791-0254

Nadiia HLADKYKH

PhD, Assistant of the Department of Internal Medicine, European Medical University, Academician Dzyak George str., 3, Dnipro, Ukraine, 49005 (nadiia.hladkykh@gmail.com)

ORCID: 0000-0003-3966-7462

Ivan KRYZHANOVSKYI

PhD, Assistant Professor of the Department of Surgical Diseases, European Medical University, Akademika Dzyaka Georgyya str., 3, Dnipro, Ukraine, 49005 (urology@i.ua)

ORCID: 0000-0003-0626-7542

To cite this article: Diudiun A., Gubar A., Polion M., Polion N., Hladkykh N., Kryzhanovskyi I. (2024). Rol infektsii, yaki perevazhno peredaiutsia statevym shliakhom, u vynyknenni ta rozvytku khronichnoho bakterialnoho prostatytu [The role of sexually transmitted infections in the onset and development of chronic bacterial prostatitis]. *Fitoterapiia. Chasopys – Phytotherapy. Journal*, 3, 79–85, doi: <https://doi.org/10.32782/2522-9680-2024-3-79>

THE ROLE OF SEXUALLY TRANSMITTED INFECTIONS IN THE ONSET AND DEVELOPMENT OF CHRONIC BACTERIAL PROSTATITIS

Actuality. Emphasizing the role of sexually transmitted infections (STIs) in the development of chronic bacterial prostatitis.

The purpose of the study is to analyze the role of STIs in the onset and development of an inflammatory process in the prostate gland.

Materials and methods. The study included 375 patients with chronic prostatitis. The average age of patients is 24.8 ± 2.4 years. Duration of the of the inflammatory process in the prostate gland for 1-3 years was 217 (32.0%), 4-6 years was 217 (57.9%), and 7–10 years was 38 (10.1%). Exacerbations of chronic disease occurred 1–2 times a year in 225 (60.0%) and 3–4 times a year in 71 (18.9%) patients. Physical, instrumental and specific laboratory tests are provided for by the regulations of the Ministry of Health of Ukraine.

Results. A comparative analysis of the course and clinical and morphological manifestations of urogenital pathology in patients. STI was detected in 252 (67.2%) patients with chronic prostatitis. The anamnesis established in 294 (78.4%) patients with chronic prostatitis was the sanitation of STIs prescription of a dermatovenerologist, urologist or treatment on the recommendation of a sexual partner. Among the identified infectious agents, a mixed chlamydial-trichomonas infection prevailed. The combination of STIs with enterobacteriaceae was detected in 272 (72.5%) patients and in 74 (19.7%) with staphylococci. In 30 (8%) patients with chronic prostatitis had a mono-infectious agent.

Conclusion. The most important sign of chronic prostatitis in men of the most sexually active age (18 to 42 years) is urethrogenic origin caused by chlamydial, trichomonas, ureaplasma and other urogenital infections, as well as their associations with opportunistic pathogens.

Key words: bacterial prostatitis, sexually-transmitted infections, transrectal ultrasound examination, chronic kidney disease, prostate-specific antigen, chlamydia, trichomoniasis, vasocongestion.

Анатолій ДЮДЮН

доктор медичних наук, професор кафедри внутрішньої медицини, Європейський медичний університет, вул. Академіка Дзяка Георгія, 3, м. Дніпро, Україна, 49005 (anatolijdudun@gmail.com)
ORCID: 0000-0003-3966-7462

Андрій ГУБАРЬ

кандидат медичних наук, доцент кафедри урології, Запорізький державний медико-фармацевтичний університет, просп. Маяковського, 26, м. Запоріжжя, Україна, 69035 (andreygubar76@gmail.com)
ORCID: 0000-0002-8198-128X

Микита ПОЛІОН

кандидат медичних наук, доцент кафедри хірургії № 1 та урології, Дніпровський державний медичний університет, вул. Володимира Вернадського, 9, м. Дніпро, Україна, 49044 (polion.mykyta@gmail.com)
ORCID: 0000-0001-9307-1411

Наталія ПОЛІОН

кандидат медичних наук, лікар-дерматовенеролог, Комунальне некомерційне підприємство «Міська клінічна лікарня № 16» Дніпровської міської ради, просп. Богдана Хмельницького, 19, м. Дніпро, Україна, 49000 (nprolion@gmail.com)
ORCID: 0000-0002-5791-0254

Надія ГЛАДКИХ

доктор філософії, асистент кафедри внутрішньої медицини, Європейський медичний університет, вул. Академіка Дзяка Георгія, 3, м. Дніпро, Україна, 49005 (nadiia.hladkykh@gmail.com)
ORCID: 0000-0003-3966-7462

Іван КРИЖАНОВСЬКИЙ

доктор філософії, асистент кафедри хірургічних хвороб, Європейський медичний університет, вул. Академіка Дзяка Георгія, 3, м. Дніпро, Україна, 49005 (urology@i.ua)
ORCID: 0000-0003-0626-7542

Бібліографічний опис статті: Дюдюн А., Губар А., Поліон М., Поліон Н., Гладких Н., Крижановський І. (2024). Роль інфекцій, які переважно передаються статевим шляхом, у виникненні та розвитку хронічного бактеріального простатиту. *Фітотерапія. Часопис*, 3, 79–85, doi: <https://doi.org/10.32782/2522-9680-2024-3-79>

РОЛЬ ІНФЕКЦІЙ, ЯКІ ПЕРЕВАЖНО ПЕРЕДАЮТЬСЯ СТАТЕВИМ ШЛЯХОМ, У ВИНИКНЕННІ ТА РОЗВИТКУ ХРОНІЧНОГО БАКТЕРІАЛЬНОГО ПРОСТАТИТУ

Актуальність. Акцентування ролі інфекцій, які передаються статевим шляхом (ІПСШ) у розвитку виникнення хронічного бактеріального простатиту.

Мета дослідження – проаналізувати роль інфекцій, які передаються статевим шляхом, у виникненні та розвитку запального процесу у передміхуровій залозі.

Матеріал і методи. Під спостереженням перебувало 375 хворих на хронічний простатит. Середній вік пацієнтів – 24,8±2,4 року. Тривалість запального процесу в передміхуровій залозі 1–3 роки становила 217 (32,0%), 4–6 років – 217 (57,9%), 7–10 років – 38 (10,1%) пацієнтів. Загострення хронічного простатиту виникали 1–2 рази на рік у 225 (60,0%), 3–4 рази на рік – у 71 (18,9%) пацієнта. Фізикальні, інструментальні та специфічні лабораторні дослідження передбачено нормативними актами МОЗ України.

Результати дослідження. Проведено порівняльний аналіз перебігу та клініко-морфологічних проявів уrogenітальної патології у пацієнтів. ІПСШ виявлено у 252 (67,2%) хворих на хронічний простатит. Зібраний анамнез установив у 294 (78,4%) пацієнтів із хронічним простатитом факт санації інфекції, що передається статевим шляхом, за призначенням дерматовенеролога, уролога або лікування за рекомендацією статевого партнера. Серед виявлених збудників інфекції переважала змішана хламідійно-трихомонадна інфекція. Поєднання ІПСШ з мікроорганізмами типу ентеробактерій виявлено у 272 (72,5%) хворих та у 74 (19,7%) – стафілококами. У 30(8%) хворих на хронічний простатит виявлено моноінфекційний агент.

Висновок. Найбільш важливою ознакою хронічного простатиту у чоловіків найбільш сексуально активного віку (від 18 до 42 років) є уретрогенне походження, спричинене хламідійною, трихомонадною, уреapлазмовою та іншими уrogenітальними інфекціями, а також їх асоціаціями з умовно-патогенними мікроорганізмами.

Ключові слова: бактеріальний простатит, інфекції, які передаються статевим шляхом, трансректальне ультразвукове дослідження, хронічна хвороба нирок, простатспецифічний антиген, хламідіоз, трихомоніаз, вазоконгестія.

Actuality. The high prevalence and problems in the treatment of patients with inflammatory diseases of the genitourinary system are often associated with not fully understood aspects of their origin and development (Jianzhong et al., 2020; Motrich et al., 2018; Papeš et al., 2017).

Chronic bacterial prostatitis (CBP) affects 20–45% of men with reduced sexual activity and significantly changes the quality of life. One of the main causes of inflammatory diseases of the genitourinary organs is various associations of infections, mostly sexually transmitted infections (STIs), such as *Chlamydia trachomatis*, *Trichomonas vaginalis*, *Mycoplasma*, *Candida*, *Herpes*, *Papillomavirus*. These infectious agents differ in their biological properties, but they lead to the formation of approximately the same lesions of the genitourinary system, which makes it possible to combine them into one group according to clinical characteristics and study the role of these pathogens in the onset and development of diseases (Etienne et al., 2019; Jianzhong et al., 2020; Papeš et al., 2017; Schuppe et al., 2017).

The prevalence of urogenital infections varies considerably among different age groups in different regions of the world, but these diseases are widespread everywhere (Jianzhong et al., 2020; Papeš et al., 2017).

The consequences of STIs in the form of chronic inflammatory diseases lead to the development of prostatitis, epididymitis and other urogenital and systemic diseases, which significantly affect the reproductive function of men (Cai et al., 2017; Diudiun et al., 2021; Schuppe et al., 2017).

Given the ability of each of the STIs and their associations to cause similar inflammatory diseases of the genitourinary system, the main task of medical tactics is timely laboratory diagnosis of the infectious agent and its prompt elimination (Bielecki et al., 2020; Cai et al., 2017; Ghobish et al., 2020; Jianzhong et al., 2020; Schuppe et al., 2017).

The spread of STIs is regulated by certain mechanisms, which include the properties of the pathogen, its virulence, immune characteristics (susceptibility of the population to the disease), and the specifics of the pathogen transmission mechanisms. (Jianzhong et al., 2020; Sheng-Jing et al., 2022).

Microbial associations contribute to the adaptation of the pathogen to intracellular parasitism and increase the pathogenicity of each pathogen, as well as its resistance to the human immune system and antibiotics. In the presence of a mix-infection, residual phenomena are often formed, which are difficult to correct and have more severe manifestations [Papeš et al., 2017; Su et al., 2020; Toth et al., 2018].

As a result of evolution, *Trichomonas vaginalis* has adapted to a special type of parasitism. *Tr. vaginalis* is capable of infecting the mucous membranes of the genitourinary system, as well as the epithelium of the genital skin, causing ulcerative and erosive processes. Penetrating into the urethra, the protozoal agent spreads over the surface of the mucous membranes and then enters the subepithelial connective tissue through the intercellular spaces, causing an inflammatory reaction. The inflammatory process is enhanced by the action of proteolytic substances on epithelial cells and subepithelial tissues produced by *Trichomonas vaginalis*. Spreading through the urethral mucosa, *Trichomonas* infect the lacunae and glands, penetrate the lymphatic spaces and blood vessels, and are transferred to the gonads, causing inflammatory changes. The normal state of the vascular walls is disturbed and abundant migration of leukocytes begins with infiltration of the upper layers of the subepithelial tissue. The urethral mucosa is infiltrated, thickens, loses elasticity, and bleeds easily. The cavities of the glands and excretory ducts are filled with leukocytes and various microorganisms [Sheng-Jing et al., 2022; Su et al., 2020; Zegarra et al., 2018; Zilbermana et al., 2017].

As the blood flow is obstructed and slowed down, microcirculation and transcapillary metabolic processes are disrupted. This leads to the development of morphofunctional changes in the pelvic organs, urodynamic disorders, which have various clinical manifestations. These changes create conditions of high vulnerability even for infectious agents with low virulence [Curtis et al., 2019; Paez-Canro et al., 2019; Zegarra Montes et al., 2018; Zilbermana et al., 2017].

Purpose. To study the role of various STIs on the course of chronic bacterial prostatitis (category II).

Material and methods. We studied 375 patients with chronic kidney disease (CKD) aged 19 to 42 years. The average age of the examined patients was 24.8 ± 2.4 years. The duration of the inflammatory process in the prostate was 1–3 years in 120 (32.0%), 4–6 years in 217 (57.9%), and 7–10 years in 38 (10.1%) patients. Exacerbations of CKD were 1–2 times per year in 225 (60.0%), 3–4 times per year in 71 (18.9%) patients. After the first complex treatment, 79 (21.1%) of the patients we observed had no exacerbation of the inflammatory process in the prostate.

The study was conducted in accordance with the principles of bioethics set forth in the Helsinki Declaration for Ethical Principles for Medical Research Involving Human Subjects and the Universal Declaration on Bioethics and Human Rights (UNESCO). The Medical Ethics Committee of the Municipal Nonprofit Enterprise «City Clinical Hospital No. 16» of the Dnipro City

Council approved the study, and each subject signed an informed consent form before the start of the study.

The diagnosis of CKD was made on the basis of patient complaints, anamnestic data, clinical manifestations, generally accepted methods of urological examination and microbiological examination of biological materials. Bacterioscopic, bacteriologic, immunologic, and molecular biologic methods were used to identify infectious agents. To exclude the possibility of malignant lesions of the prostate gland, the level of serum prostate-specific antigen (PSA) was determined in the patients under observation. All patients underwent general clinical examinations and, if indicated, consultations with other specialists.

When examining patients with CKD, we took into account the standard, which includes four symptom complexes of this disease: pain, dysuria, and disorders of the reproductive system. Each of these symptom complexes was considered as the only one or was the main one in the complex of clinical manifestations of the disease.

Patients underwent ultrasound examination using an ACUSON 128 XP/10 ultrasound scanner and an Aloka SSD-1400 ultrasound scanner with a 3.5 MHz convection transducer for transabdominal scanning. Transrectal examination in halftone mode was performed according to the generally accepted method.

To detect abnormalities in prostate hemodynamics, the method of transrectal ultrasound Doppler (TRUSDG) with color mapping was used on the Acuson Sequoia 512 (Japan) with a 7.0 MHz sensor. To assess arterial blood flow in the prostate gland, the quantitative angular parameter of peak (maximum) systolic velocity (V_{max}) was used in relation to the central zone (blood flow in the prostatic and urethral arteries) and the peripheral zone of the prostate (blood flow in the capsular arteries). The average blood flow velocity was used to assess venous blood flow.

To assess peripheral resistance, the calculated Pursilol's resistivity index (IR) was used. Statistical processing of the study results was performed using the method of biometric analysis implemented using licensed software packages Excel-2003® Statistica 6.1 (StatSoft Inc., serial number AGAR909E415822FA) [Papeš et al., 2017].

Research results and discussion. In most cases, the inflammatory process in CKD proceeds as primary chronic. Patients complained of generalized weakness, fatigue, and subfebrile temperature.

Lower abdominal and perineal pain was reported by 296 (78.9%) patients. According to various authors, pain in prostatitis is one of the leading clinical symptoms and reaches 82% [Nathan et al., 2021]. The localization and intensity of pain in the patients we examined were

mosaic in nature. The pain increased during prolonged sitting, defecation, and physical activity. More than 30% of patients with chronic prostatitis (CP) reported a feeling of incomplete bladder emptying.

Among the dysuric disorders fig. 1, which were reported by our patients, were: 315 (84%) – pollakiuria, 326 (86.9%) – nocturia, 195 (52%) – sluggish urine output, 67 (17.9%) – stranguria. The manifestations of dysuric disorders in our patients with CKD are caused not only by urethral inflammation, but also by the involvement of the bladder neck in the process. According to the literature, urinary disorders overwhelmingly accompany the clinic of prostatitis and are also a leading clinical symptom [Imothy et al., 2016; Lin et al., 2023; Schuppe et al., 2017].




Fig. 1. Frequency of dysuric disorders among the examined patients

Finger rectal examination of the prostate revealed its enlargement in 322 (85.9%) patients, decreased tone in 247 (65.9%) patients, compaction and retraction of the gland in 183 (48.8%), and doughy consistency of the gland in 22 (18.9%). Palpation of the prostate was painful in 262 (69.9%) patients, and smoothness of the interlobular furrow – in 116 (30.9%). Changes in the prostate during finger rectal examination, characteristic of CP, range from 20.5% to 68% according to studies by various authors [Bielecki et al., 2020].

The study of prostate express in 332 (88.5%) patients revealed the presence of more than 10 leukocytes in the high-magnification field, and in 225 (60.0%) patients – a reduced number of lecithin grains. In all the studied cases, the titer of bacterial contamination of the prostate express was diagnostically significant (> 103 CFU/ml).

Carefully and purposefully collected anamnesis made it possible to establish in 294 (78.4%) patients with CKD the fact of STI sanitation as prescribed by a dermatovenerologist, urologist or treatment on the recommendation of a sexual partner.

A comprehensive examination of 375 patients with CKD revealed STIs in 252 (67.2%) patients (fig. 2). Mixed

chlamydial-trichomonas infection prevailed among the identified pathogens. The combination of STIs with microorganisms such as enterobacteriaceae was detected in 272 (72.5%), and in 74 (19.7%) – with staphylococci. Only 30 (8%) patients with CP had a mono-infectious agent.




Fig. 2 Frequency of exposure to infectious agents in patients with chronic prostatitis

Obligate chlamydial infection is characterized by an initially asymptomatic or slightly asymptomatic course, and therefore is often diagnosed late or with the development of residual effects. Moreover, in men, total damage to the urethra and prostate gland is usually observed during this period. It should also be noted that trichomoniasis of the genitourinary tract is very often the cause of the onset and development of prostatitis. The latter is due to the fact that in men, the prostate gland and seminal vesicles are a frequent habitat for trichomonads. In this case, clinical signs of the disease can be extremely scarce or completely absent for a long time. Despite the prolonged asymptomatic course of chronic prostatitis caused by *Trichomonas*, the pathogenicity of *Tr. vaginalis* persists and is transmitted to the sexual partner. Periodic, so-called «causeless» urethritis is possible throughout the course of CKD. The absence of an epidemiologic history of «causeless» urethritis has created a condition under which this group of patients is not given due attention. According to a number of authors, mixed infection in patients with prostatitis is detected in 12.3 to 78.4% of cases [Curtis et al., 2019; Su et al., 2020; Toth et al., 2018].

Transrectal ultrasound (TRUS) in 311 (82.9%) patients revealed an increase in the size of the prostate, in 42 (11.2%) – normal size and in 22 (5.9%) – a decrease in the size of the gland.

Ultrasound Doppler revealed vascular architectural disorders in 327 (87.2%) patients: in 263 (70.1%) – decreased vascularization, in 75 (20.0%) – increased vascularization, and only in 37 (9.9%) – normal prostate vascularization. Hemodynamic disorders in patients with CKD were observed both with normal prostate size and with its enlarged size. Hemodynamic disorders of

the prostate gland prevail in patients with enlarged prostate. According to E.Zilberman's research, foci of sclerosis, heteroechoic heterogeneity, increased prostate size, local and diffuse changes in prostate hemoperfusion are detected in 69.2% to 79.8% of cases [Cai et al., 2017].

Thus, in the examined patients, an increase in prostate size was associated with vasocongestion, and a decrease in prostate size was associated with the development of fibrosis in certain areas of the gland with a more pronounced process in the peripheral zone. Changes in hemodynamics in the venous vessels reflect the presence of vasocongestive phenomena and contribute to the maintenance of chronic inflammation of the prostate gland and its relapses.

Changes in the prostate suggest the presence of pre-existing foci of the infectious and inflammatory process. Chronic prostatitis occurs, as a rule, in patients with infectious urethritis who have not received treatment or have received therapy insufficient to completely destroy the infectious agent and restore the mucous membrane.

In cases of a combination of congestion and an infectious factor, the so-called infectious nonspecific or specific (with chlamydia, trichomoniasis and other microbial pathogens) prostatitis develops.

Thus, according to the results of our study, the most important feature of chronic prostatitis in men of the most sexually active age (18 to 42 years) is its urethrogenic origin, which is caused by chlamydia, trichomonas, ureaplasma and other STIs as their association with opportunistic pathogens.

Conclusions

1. The results of a comprehensive examination of patients with chronic prostatitis and epidemiological analysis suggest the role of sexually transmitted infections in the onset and development of pathological processes in the prostate gland in men of the most sexually active age. A comprehensive examination of 375 patients with chronic prostatitis revealed sexually transmitted infections in 252 (67.2%) patients. Mixed chlamydial-trichomonas infection prevailed among the identified pathogens. The combination of sexually transmitted infections with microorganisms such as enterobacteriaceae was detected in 272 (72.5%), and in 74 (19.7%) – with staphylococci. Only 30 (8%) patients with chronic prostatitis had a mono-infectious agent.

2. All patients with chronic prostatitis and their sexual partners, especially young men, should be re-examined for sexually transmitted infections.

3. Implementation of the rule «failure to detect an infectious agent in a sexual partner does not exclude a diagnosis» will contribute to both early detection and eradication of sexually transmitted infections and prevention of chronic prostatitis.

BIBLIOGRAPHY

- Ammar Ghobish Voiding Dysfunction Associated with “Chronic Bacterial Prostatitis” *European Urology* Volume 42, Issue 2, August 2020, Pages 159–162. [https://www.europeanurology.com/article/S0302-2838\(02\)00258-0/fulltext](https://www.europeanurology.com/article/S0302-2838(02)00258-0/fulltext)
- Bielecki R, Ostaszewska-Puchalska I, Zdrodowska-Stefanow B, Baltaziak M, Skawrońska M, Sokołowska M. The presence of Chlamydia trachomatis infection in men with chronic prostatitis. *Cent European J Urol.* 2020;73(3):362–368. <https://doi.org/10.5173/ceju.2020.0040>
- Cai T, Pisano F, Nesi G, Magri V, Verze P, Perletti G, Gontero P, Mirone V, Bartoletti R. Chlamydia trachomatis versus common uropathogens as a cause of chronic bacterial prostatitis: Is there any difference? Results of a prospective parallel-cohort study. *Investig Clin Urol.* 2017 Nov; 58(6):460–467. <https://doi.org/10.4111/icu.2017.58.6.460>
- Curtis Nickel J., MD, FRCSC. Lower urinary tract symptoms associated with prostatitis *Can Urol Assoc J.* 2019 Oct; 6(5 Suppl 2): S133–S135. doi: 10.5489/cuaj.12201 PMID: PMC3481939 PMID: 23092777 <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481939/>
- Diudiun A.D., Polion M.Y., Polion N.N. Nosomorphosis of diseases caused by urogenital infections. *Medicini perspektivi.* 2021; 26(3):114–118. <https://doi.org/10.26641/2307-0404.2021.3.242083>.
- E. Zilbermana, Matvey Tsivianb, Yoram Mora Gil Ravivac The trues behind TRUS in the setting of chronic prostatitis/chronic pelvic pain syndrome *Urological Science* Volume 27, Issue 1, March 2017, Pages 40–44 <https://doi.org/10.1016/j.urols.2015.04.006> <https://www.sciencedirect.com/science/article/pii/S1879522615000664>
- Imothy J. Coker, MD, Daniel M. Dierfeldt, Ehrling Bergquist Acute Bacterial Prostatitis: Diagnosis and Management. *Family Medicine Residency Program, Offutt Air Force Base, Nebraska Am Fam Physician.* 2016 Jan 15;93(2):114–120. <https://www.aafp.org/afp/2016/0115/p114.html>
- Jianzhong Zhang, ChaoZhao Liang, Xuejun Shang Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom? Current Perspectives on Diagnosis, Treatment, and Prognosis. *Am J Mens Health.* Jan-Feb 2020;14(1):1557988320903200. <https://doi.org/10.1177/1557988320903200>.
- L. R. Zegarra Montes, A. A. Sanchez Mejia, C. A. Loza Munarriz, E. Celis Gutierrez Semen and Urine Culture in the Diagnosis of Chronic Bacterial Prostatitis *Clinical Urology Chronic Bacterial Prostatitis International Braz J Urol* Vol. 34(1): 30–40, February, 2018 <https://www.scielo.br/j/ibju/a/VD3L47yGcmSRJJV6Fw6nxK/?format=pdf&lang=en>
- Lin W, Wang Y, Chen Y. Efficacy Analysis of Physical Therapy in Treating Chronic Prostatitis: Unblocking Obstructed Glandular Ducts Could Be a Novel Treatment Strategy. *Res Rep Urol.* 2023;15:553–561. <https://doi.org/10.2147/RRU.S442844>
- Manuel Etienne, Pascal Chavanet, Louis Sibert, Frédéric Michel, Hervé Levesque, Bernard Lorcerie, Jean Doucet/ Pierre Pfitzenmeyer & François Caron, November 2019. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis DOI <https://doi.org/10.1186/1471-2334-8-12>
- Motrich RD, Salazar FC, Bresler ML, Mackern-Oberti JP, Godoy GJ, Olivera C, Paira DA, Rivero VE. Implications of prostate inflammation on male fertility. *Andrologia.* 2018 Dec; 50(11): e13093. <https://doi.org/10.1111/and.13093>
- Nathan G. Davis; Michael Silberman. Bacterial Acute Prostatitis University of Tennessee Last Update: October 7, 2021. <https://www.ncbi.nlm.nih.gov/books/NBK459257/> Bookshelf ID: NBK459257 PMID: 29083799
- Páez-Canro C, Alzate JP, González LM, Rubio-Romero JA, Lethaby A, Gaitán HG. Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. *Cochrane Database Syst Rev.* 2019 Jan 25; 1(1): CD010871. <https://doi.org/10.1002/14651858.CD010871.pub2>.
- Papeš D, Pasini M, Jerončić A, Vargović M, Kotarski V, Markotić A, Škerk V. Detection of sexually transmitted pathogens in patients with chronic prostatitis/ chronic pelvic pain: a prospective clinical study. *Int J STD AIDS.* 2017 May; 28(6):613–615. <https://doi.org/10.1177/0956462417691440>.
- Schuppe HC, Pilatz A, Hossain H, Diemer T, Wagenlehner F, Weidner W. Urogenital Infection as a Risk Factor for Male Infertility. *Dtsch Arztebl Int.* 2017 May 12; 114(19):339–346. <https://doi.org/10.3238/arztebl.2017.0339>.
- Sheng-Jing Liu, Qing-He Gao, Ying-Jun Deng, Yin Zen, Ming Zhao, Jun Guo. Knowledge domain and emerging trends in chronic prostatitis/ chronic pelvic pain syndrome from 1970 to 2020: a scientometric analysis based on VOS viewer and Cite Space PMID: 35144392 DOI: 10.21037/apm-21-3068 2022 Feb 9.
- Su, Z.T., Zenilman, J.M., Sfanos, K.S. et al. Management of Chronic Bacterial Prostatitis. *Curr Urol Rep* 21, 29 (2020). <https://doi.org/10.1007/s11934-020-00978-z>
- Toth A, Guercini FM, Feldthouse DM, Zhang JC. Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases. *Arch Ital Urol Androl.* 2018 Mar 31; 90(1):34–39. <https://doi.org/10.4081/aiua.2018.1.34>

REFERENCES

- Ammar Ghobish Voiding Dysfunction Associated with “Chronic Bacterial Prostatitis” *European Urology* Volume 42, Issue 2, August 2020, Pages 159–162. Retrieved from [https://www.europeanurology.com/article/S0302-2838\(02\)00258-0/fulltext](https://www.europeanurology.com/article/S0302-2838(02)00258-0/fulltext)
- Bielecki, R, Ostaszewska-Puchalska, I, Zdrodowska-Stefanow, B, Baltaziak, M, Skawrońska, M, & Sokołowska, M. (2020). The presence of Chlamydia trachomatis infection in men with chronic prostatitis. *Cent European J Urol.* 73(3): 362–368. <https://doi.org/10.5173/ceju.2020.0040>
- Cai, T, Pisano, F, Nesi, G, Magri, V, Verze, P, Perletti, G, Gontero, P, Mirone, V, Bartoletti, R. (2017). Chlamydia trachomatis versus common uropathogens as a cause of chronic bacterial prostatitis: Is there any difference? Results of a prospective parallel-cohort study. *Investig Clin Urol.* Nov; 58(6):460–467. <https://doi.org/10.4111/icu.2017.58.6.460>
- Curtis Nickel J., MD, FRCSC. (2019). Lower urinary tract symptoms associated with prostatitis *Can Urol Assoc J.* Oct; 6(5 Suppl 2): S133–S135. doi: 10.5489/cuaj.12201 PMID: PMC3481939 PMID: 23092777 Retrieved from <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3481939/>

Diudiun, A.D., Polion, M.Y., Polion, N.N. (2021). Nosomorphosis of diseases caused by urogenital infections. *Medicni perspektivi*. 26(3):114–118. <https://doi.org/10.26641/2307-0404.2021.3.242083>.

E. Zilbermana, Matvey Tsivianb, Yoram Mora Gil Ravivac The trues behind TRUS in the setting of chronic prostatitis/chronic pelvic pain syndrome *Urological Science* Volume 27, Issue 1, March 2017, Pages 40–44 <https://doi.org/10.1016/j.urols.2015.04.006> Retrieved from <https://www.sciencedirect.com/science/article/pii/S1879522615000664>

Imothy J. Coker, MD, Daniel M. Dierfeldt. Ehrling Bergquist Acute Bacterial Prostatitis: Diagnosis and Management. *Family Medicine Residency Program, Offutt Air Force Base, Nebraska Am Fam Physician*. 2016 Jan 15;93(2):114–120. <https://www.aafp.org/afp/2016/0115/p114.html>

Jianzhong Zhang, ChaoZhao Liang, Xuejun Shang Chronic Prostatitis/Chronic Pelvic Pain Syndrome: A Disease or Symptom? Current Perspectives on Diagnosis, Treatment, and Prognosis. *Am J Mens Health*. Jan-Feb 2020.14(1):1557988320903200. <https://doi.org/10.1177/1557988320903200>.

L. R. Zegarra Montes, A. A. Sanchez Mejia, C. A. Loza Munarriz, E. Celis Gutierrez Semen and Urine Culture in the Diagnosis of Chronic Bacterial Prostatitis *Clinical Urology Chronic Bacterial Prostatitis International Braz J Urol* Vol. 34(1): 30–40, February, 2018 <https://www.scielo.br/j/ibju/a/VD3L47yGcmSRJVV6Fw6nxK/?format=pdf&lang=en>

Lin, W, Wang, Y, & Chen, Y. (2023). Efficacy Analysis of Physical Therapy in Treating Chronic Prostatitis: Unblocking Obstructed Glandular Ducts Could Be a Novel Treatment Strategy. *Res Rep Urol*. 15:553–561. <https://doi.org/10.2147/RRU.S442844>

Manuel Etienne, Pascal Chavanet, Louis Sibert, Frédéric Michel, Hervé Levesque, Bernard Lorcerie, Jean Doucet/ Pierre Pfitzenmeyer & François Caron, November 2019. Acute bacterial prostatitis: heterogeneity in diagnostic criteria and management. Retrospective multicentric analysis of 371 patients diagnosed with acute prostatitis DOI <https://doi.org/10.1186/1471-2334-8-12> Retrieved from

Motrich, RD, Salazar, FC, Breser, ML, Mackern-Oberti, JP, Godoy, GJ, Olivera, C, Paira, DA, Rivero, VE. (2018). Implications of prostate inflammation on male fertility. *Andrologia*Dec; 50(11): e13093. <https://doi.org/10.1111/and.13093>

Nathan, G. Davis; Michael, Silberman. Bacterial Acute Prostatitis University of Tennessee Last Update: October 7, 2021. Retrieved from <https://www.ncbi.nlm.nih.gov/books/NBK459257/> Bookshelf ID: NBK459257PMID: 29083799

Páez-Canro, C, Alzate, JP, González, LM, Rubio-Romero, JA, Lethaby, A, Gaitán, HG. (2019). Antibiotics for treating urogenital Chlamydia trachomatis infection in men and non-pregnant women. *Cochrane Database Syst Rev*. Jan 25; 1(1): CD010871. <https://doi.org/10.1002/14651858.CD010871.pub2>.

Papeš, D, Pasini, M, Jerončić, A, Vargović, M, Kotarski, V, Markotić, A, Škerk, V. (2017). Detection of sexually transmitted pathogens in patients with chronic prostatitis/ chronic pelvic pain: a prospective clinical study. *Int J STD AIDS*. May; 28(6):613–615. <https://doi.org/10.1177/0956462417691440>.

Schuppe, HC, Pilatz, A, Hossain, H, Diemer, T, Wagenlehner, F, Weidner, W. (2017). Urogenital Infection as a Risk Factor for Male Infertility. *Dtsch Arztebl Int*. May 12; 114(19):339–346. <https://doi.org/10.3238/arztebl.2017.0339>.

Sheng-Jing Liu, Qing-He Gao, Ying-Jun Deng, Yin Zen, Ming Zhao, Jun Guo. Knowledge domain and emerging trends in chronic prostatitis/ chronic pelvic pain syndrome from 1970 to 2020: a scientometric analysis based on VOS viewer and Cite Space PMID: 35144392 DOI: 10.21037/apm-21-3068 2022 Feb 9.

Su, Z.T., Zenilman, J.M., Sfanos, K.S. et al. (2020). Management of Chronic Bacterial Prostatitis. *Curr Urol Rep* 21, 29 <https://doi.org/10.1007/s11934-020-00978-z>

Toth, A, Guercini, FM, Feldthouse, DM, Zhang, JC. (2018). Injection therapy for chronic prostatitis: A retrospective analysis of 77 cases. *Arch Ital Urol Androl*. Mar 31; 90(1):34–39. <https://doi.org/10.4081/aiua.2018.1.34>

Стаття надійшла до редакції 10.05.2024.

Стаття прийнята до друку 28.06.2024.

The authors declare no conflict of interest.

Authors' contributions:

Diudiun A. – development of the study concept, idea of the study design, correction of the clinical section;

Gubar A. – statistical processing of the clinical section of the work, conclusions, summary;

Polion M. – analysis of the results, abstracts, choice of research strategy;

Polion N. – interpretation of the results, justification of the purpose and objectives of the study, summary;

Hladkykh N. – collection and analysis of literature, correction of the work performed, participation in writing the article;

Kryzhanovskiy I. – correction and literary editing.

E-mail address for correspondence with the authors: nadiia.hladkykh@gmail.com.